127510-94-5

Basic information

• Product Name: 2-cyano-5-methyl-benzoic acid methyl ester
• Synonyms: 2-cyano-5-methyl-benzoic acid methyl ester;Benzoic acid, 2-cyano-5-methyl-, methyl ester;methyl 2-cyano-5-methylbenzoate
• CAS NO: 127510-94-5
• Molecular Formula: C₁₀H₉NO₂
• Molecular Weight: 175.18396
• Mol File: 127510-94-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 316.4±30.0 °C(Predicted)
• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 2-cyano-5-methyl-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-cyano-5-methyl-benzoic acid methyl ester(127510-94-5)
• EPA Substance Registry System: 2-cyano-5-methyl-benzoic acid methyl ester(127510-94-5)

Safety Data

• Hazardous Substances Data: 127510-94-5(Hazardous Substances Data)

Upstream product

• 52548-14-8 2-iodoyl-5-methylbenzoic acid 
• 18595-16-9 2-amino-5-methylbenzoic acid methyl ester 
• 12150-46-8 1,1'-bis(diphenylphosphino)ferrocene 
• 103440-52-4 methyl 2-iodo-5-methylbenzoate 
• 20587-30-8 5-methyl-2-nitro-benzoic acid methyl ester 
• 557-21-1 dicyanozinc 
• 151-50-8 potassium cyanide 

Downstream Products

• 4316-23-8 4-methylphthalic acid 
• 308845-91-2 methyl 2-cyano-5-bromomethylbenzoate 
• 308845-92-3 methyl 2-cyano-5-(N,N-tert-butyloxycarbonylaminomethyl)benzoate 

Relevant articles and documents

Design, synthesis and identification of novel colchicine-derived immunosuppressant

Synthesis and biological evaluation of various colchicine analogues through the mixed-lymphocyte reaction (MLR), lymphoproliferation, and inhibitory effects on the inflammatory genes are described. In addition, a new series of immunosuppressive agents developed on the structural basis of colchicine, as well as their structure-activity relationships is reported. The most potent analogue 20a exhibited an excellent immunosuppressive activity on in vivo skin-allograft model, which is comparable to that of cyclosporin A.

Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade

The invention relates to substituted polycyclic aryl and heteroaryl pyrazinone compounds useful as inhibitors of serine proteases of the coagulation cascade and compounds, compositions and methods for anticoagulant therapy for the treatment and prevention of a variety of thrombotic conditions including coronary artery and cerebrovascular diseases.